Mats Heyman

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 22

Top Topics

Prognostic Factors

Top Venues

Acta paediatrica (Oslo, Norway : 1992)

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, Chihaya Imai, Toshihiko Imamura, Mats Heyman, Kjeld Schmiegelow, Rob Pieters
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia 38 (7) (2024)
Merete Dam, Maddalena Centanni, Lena E Friberg, Daniel Centanni, Mats O Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Ulrik Overgaard, Kjeld Schmiegelow, Stefan Nygaard Hansen, Mats Heyman, Birgitte Klug Albertsen
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia 38 (4) (2024)
Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, Chihaya Imai, Toshihiko Imamura, Mats Heyman, Kjeld Schmiegelow, Rob Pieters
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia (2024)
Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, Chihaya Imai, Toshihiko Imamura, Mats Heyman, Kjeld Schmiegelow, Rob Pieters
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia 38 (7) (2024)
Anthony V Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L Den Boer, Rob Pieters, Valerie de Haas, Martin A Horstmann, Gabriele Escherich, Bertil Johansson, Hanne Vibeke Hansen Marquart, Kjeld Schmiegelow, Jeremy Hancock, John P Moppett, Mats Heyman
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia (2024)
Susanna Ranta, Lars Mikael Broman, Karin Mellgren, Ulrika Norén-Nyström, Johan E Svahn, Lisa Törnudd, Mats Heyman, Arja Harila
Intensive care in children with non-Hodgkin lymphoma in Sweden. Acta paediatrica (Oslo, Norway : 1992) 113 (8) (2024)
Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, Chihaya Imai, Toshihiko Imamura, Mats Heyman, Kjeld Schmiegelow, Rob Pieters
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia 38 (7) (2024)
Merete Dam, Maddalena Centanni, Lena E Friberg, Daniel Centanni, Mats O Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Ulrik Overgaard, Kjeld Schmiegelow, Stefan Nygaard Hansen, Mats Heyman, Birgitte Klug Albertsen
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia 38 (4) (2024)
Anthony V Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L Den Boer, Rob Pieters, Valerie de Haas, Martin A Horstmann, Gabriele Escherich, Bertil Johansson, Hanne Vibeke Hansen Marquart, Kjeld Schmiegelow, Jeremy Hancock, John P Moppett, Mats Heyman
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia 38 (9) (2024)
Merete Dam, Maddalena Centanni, Lena E Friberg, Daniel Centanni, Mats O Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Ulrik Overgaard, Kjeld Schmiegelow, Stefan Nygaard Hansen, Mats Heyman, Birgitte Klug Albertsen
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia (2024)
Susanna Ranta, Lars Mikael Broman, Karin Mellgren, Ulrika Norén-Nyström, Johan E Svahn, Lisa Törnudd, Mats Heyman, Arja Harila
Intensive care in children with non-Hodgkin lymphoma in Sweden. Acta paediatrica (Oslo, Norway : 1992) (2024)
Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, Chihaya Imai, Toshihiko Imamura, Mats Heyman, Kjeld Schmiegelow, Rob Pieters
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure? Leukemia 38 (7) (2024)
Merete Dam, Maddalena Centanni, Lena E Friberg, Daniel Centanni, Mats O Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Ulrik Overgaard, Kjeld Schmiegelow, Stefan Nygaard Hansen, Mats Heyman, Birgitte Klug Albertsen
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia 38 (4) (2024)
Merete Dam, Maddalena Centanni, Lena E Friberg, Daniel Centanni, Mats O Karlsson, Line Stensig Lynggaard, Inga Maria Johannsdottir, Hilde Skuterud Wik, Johan Malmros, Goda Elizabeta Vaitkeviciene, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Ulrik Overgaard, Kjeld Schmiegelow, Stefan Nygaard Hansen, Mats Heyman, Birgitte Klug Albertsen
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia 38 (4) (2024)
Anthony V Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L Den Boer, Rob Pieters, Valerie de Haas, Martin A Horstmann, Gabriele Escherich, Bertil Johansson, Hanne Vibeke Hansen Marquart, Kjeld Schmiegelow, Jeremy Hancock, John P Moppett, Mats Heyman
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia 38 (9) (2024)
Anthony V Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L Den Boer, Rob Pieters, Valerie de Haas, Martin A Horstmann, Gabriele Escherich, Bertil Johansson, Hanne Vibeke Hansen Marquart, Kjeld Schmiegelow, Jeremy Hancock, John P Moppett, Mats Heyman
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia 38 (9) (2024)
Johannes Fermér, Jonas Jalnäs, Jonas Abrahamsson, Magnus Borssen, Isabella Donnér, Ludvig Henriksson, Mats Heyman, Anna Sällfors Holmqvist, Anders Valind, Hartmut Vogt, Anne Wretman, Otto Zhou, Arja Harila, Susanna Ranta
Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the ALLTogether protocol. Acta paediatrica (Oslo, Norway : 1992) (2024)
Karen Schow Jensen, Trausti Oskarsson, Päivi Maria Lähteenmäki, Trond Flaegstad, Ólafur Gísli Jónsson, Petter Svenberg, Kjeld Schmiegelow, Mats Heyman, Ulrika Norén-Nyström, Henrik Schrøder, Birgitte Klug Albertsen
Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study. Leukemia 36 (5) (2022)
Benedicte Bang, Jesper Eisfeldt, Gisela Barbany, Arja H Harila-Saari, Mats Heyman, Vasilios Zachariadis, Fulya Taylan, Ann Nordgren
A somatic UBA2 variant preceded ETV6-RUNX1 in the concordant BCP-ALL of monozygotic twins. Blood advances 6 (7) (2022)
Susanna Ranta, Lars Mikael Broman, Jonas Abrahamsson, Lene Karlsson, Ulrika Norén-Nyström, Josefine Palle, Johan E Svahn, Lisa Törnudd, Mats Heyman, Arja Harila-Saari
High need for intensive care in paediatric acute myeloid leukaemia: A population-based study. Acta paediatrica (Oslo, Norway : 1992) 111 (11) (2022)
Swantje Buchmann, Martin Schrappe, Andre Baruchel, Andrea Biondi, Michael J Borowitz, Myriam Campbell, Gunnar Cario, Giovanni Cazzaniga, Gabrielle Escherich, Christine J Harrison, Mats Heyman, Stephen P Hunger, Csongor Kiss, Hsi-Che Liu, Franco Locatelli, Mignon L Loh, Atsushi Manabe, Georg Mann, Rob Pieters, Ching-Hong Pui, Susana Rives, Kjeld Schmiegelow, Lewis B Silverman, Jan Stary, Ajay Vora, Patrick A Brown
Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. Blood (2021)
Line Stensig Lynggaard, Cecilie Utke Rank, Stefan Nygaard Hansen, Sofie Gottschalk Højfeldt, Louise Tram Henriksen, Kirsten Brunswig Jarvis, Susanna Ranta, Riitta Niinimäki, Arja Harila-Saari, Benjamin Ole Wolthers, Thomas Leth Frandsen, Mats Heyman, Kjeld Schmiegelow, Birgitte Klug Albertsen
Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study. Blood advances (2021)